Testing TRYPTYR Eye Drops for Dry Eye Disease in Adults with Sjgrens Syndrome

What this Trial Is About

Researchers are evaluating TRYPTYR Acoltremon ophthalmic solution 0.003% as a new treatment for dry eye disease caused by Sjf6grens Syndrome. This Phase 4 study aims to determine whether TRYPTYR can improve symptoms and signs of dry eye in adults diagnosed within the past two years who have used or desire artificial tears recently. Participants will receive TRYPTYR drops in the study eye, which is determined by the lower baseline Schirmer score without anesthesia. The drops are instilled before and after measuring the eyes tear production and corneal staining. The primary measurement is the change in tear production 3 minutes after applying TRYPTYR, assessed at the first visit. During the study, participants will undergo tear production tests, corneal staining assessments, and safety monitoring. They must avoid certain medications and contact lenses during the trial. The study tracks changes in dry eye signs shortly after treatment to evaluate TRYPTYRs effects. Participation involves scheduled visits for these evaluations up to the studys end date in December 2026.

Evaluating a New Therapy for Dry Eye in Patients With Sjögren's Syndrome